Regeneron +13%, CareDx +22%: Monday's High-Volume Breakouts
Regeneron surges 13% toward a 52-week high while CareDx explodes 22% on massive volume. Monday's top earnings and catalyst movers, ranked by real volume.
Key Points
- Regeneron is up 13.33% to $927.89 on 2.85 million shares — nearly four times average volume — and is within $7.46 of its 52-week high of $935.35.
- CareDx has surged 22.22% to $87.41 on volume nearly three times its daily average, extending a year-to-date gain of 491.81% that makes it one of 2026's defining single-stock stories.
- Traders should watch whether REGN tags and holds above its $935.35 52-week high, which would represent a technical breakout with momentum confirmation from today's volume surge.
Regeneron is up $109.12, or 13.33%, to $927.89 Monday morning on 2.85 million shares — nearly four times its 733,000-share daily average — and is within striking distance of its 52-week high of $935.35. That $7.46 gap to the 52-week high is the number every momentum trader in biotech is watching right now. At this trajectory, it could close before lunch.
The Real Volume Leaders
Before chasing anything green on a Monday, the first filter has to be volume confirmation. Price moves without volume are noise; price moves on 2x to 4x average daily volume with a clear fundamental catalyst are tradeable signals. Monday's gainer board has several that clear that bar — and a few that absolutely do not.
Regeneron's move is the cleanest setup of the morning. The stock is trading at $927.89 with a 52-week high of $935.35 sitting directly overhead, and the volume is unambiguously institutional — 2.85 million shares against a 733,000-share average is not retail momentum chasing. That is funds adding. The specific catalyst driving the move was not available at press time, but the magnitude and volume profile are consistent with either a significant clinical data release or a meaningful earnings beat. Biotech stocks at this price level — nearly $1,000 per share — do not move 13% on rumor. Something landed.
CareDx is the year-to-date story that Monday's move adds another chapter to. CDNA is up 22.22% to $87.41 on 3.55 million shares, against an average of 1.3 million — a 2.7x volume multiple. The more striking number is the year-to-date return: +491.81%. For context, that means a $20,000 position in CDNA on January 1 is worth roughly $118,000 today. The transplant diagnostics company has been one of the most discussed names on institutional biotech desks all year, and Monday's surge — whatever the catalyst — is landing on a stock that already has enormous embedded gains and, therefore, enormous embedded selling pressure. The risk with CDNA at this price is exactly that: every 20% pop creates a cohort of investors who have been waiting to exit at a profit, and the stock can reverse violently if the catalyst proves temporary.
FedEx Freight Holding is the industrial story of the morning. FDXF is up 14.91% to $126.04 on 3.59 million shares versus a 1.5 million average — its own 2.4x volume multiple, and the heaviest raw share count among the major gainers outside of the micro-cap momentum names. FedEx Freight was spun off from FedEx Corp earlier this year, and the post-spinoff price discovery process has been volatile. A double-digit move on this kind of volume in a freight company is worth watching for what it implies about shipping demand and margin recovery in the industrial logistics sector. If FDXF is pricing in better-than-expected freight volumes, that's a read-through to the broader industrial tape.
Separating Signal From Noise
Three names on Monday's alert board deserve a different kind of attention — specifically, the attention you give to a live wire before you touch it. Inovio Pharmaceuticals is up 223% on volume that is 2,114 times its normal daily average, with 7.0 million shares changing hands. ClearOne is up 78% on 3,600 times normal volume. 22nd Century Group has gained 41% on 3,657 times normal volume with 108.4 million shares — a number that implies nearly the entire outstanding float has turned over multiple times today.
These are not investment theses. They are volatility events. Stocks moving 78% to 223% on thousands of times normal volume are being driven by retail momentum, short squeezes, or binary event resolution — clinical trial data, FDA decisions, or news that changes the total addressable market overnight. The spread between bid and ask on these names in real trading conditions is punishing, the halts are unpredictable, and the reversals are typically as violent as the initial spike. The right size for these, if you trade them at all, is a size you can afford to watch go to zero before the afternoon session ends. That is not hyperbole. That is the empirical track record of triple-digit single-day movers on micro-cap biotech and nano-cap tech names.
The more actionable large-cap pre-market picture belongs to a cluster of names showing 3% to 6% gains on earnings catalysts. Regeneron leads at +6.24% in large-cap pre-market ranking, followed by Mondelez International at +4.64%, Equifax at +4.26%, Colgate-Palmolive at +4.20%, and Gilead Sciences at +3.23%. Each of those moves reflects a specific earnings result or guidance revision — the kind of catalyst that creates multi-day price discovery, not a single-session spike and reversal.
The Catalyst Pipeline Into the Close
GoDaddy deserves a specific mention. GDDY is up 10.72% to $117.24 on 3.38 million shares against a 2.1 million average — a clean 1.6x volume multiple. GoDaddy has been quietly repositioning itself as an AI-tools platform for small businesses over the past 18 months, and a double-digit move on above-average volume is consistent with a strong earnings print showing that the pivot is generating revenue. The stock is one of the few large-cap tech-adjacent names showing momentum on a day when the broader Nasdaq is still trying to find its footing after October's 5.2% decline.
BrightSpring Health Services is Monday's volume leader by raw share count among the major gainers — 5.91 million shares changing hands for a gain of 11.08% to $66.89. BTSG operates in home and community-based health services, a sector that has been gaining institutional interest as the post-pandemic healthcare infrastructure debate focuses on reducing hospital-centric cost structures. Nearly 6 million shares on a name that doesn't typically attract this kind of activity suggests something fundamental happened — earnings, a guidance revision, or an M&A signal. Traders watching BTSG should pull the news feed carefully before interpreting this as pure momentum.
The evening earnings slate creates a direct feedback loop for several of today's movers. Apple's result will reset the psychological baseline for large-cap tech. Palantir's print will either validate or invalidate the AI enterprise spending narrative that caused October's damage. Berkshire Hathaway's filing will be parsed for Warren Buffett's equity allocation changes — specifically, whether the $320 billion cash pile was deployed, reduced, or extended. Any surprise holding disclosures in Berkshire's 13-F-equivalent filings can move individual stocks significantly. The specific level to watch on Regeneron is $935.35 — the 52-week high that today's move is testing. A clean close above that level on volume of 3 million-plus shares would be a genuine technical breakout. A fade back below $910 on volume deceleration into the afternoon would be a textbook rejection at resistance, and the gap from this morning's opening print would become the new overhead supply.
The Weekly Investor
Daily market analysis for active traders. Free.
